Welcome to our dedicated page for Xenetic Biosciences news (Ticker: XBIO), a resource for investors and traders seeking the latest updates and insights on Xenetic Biosciences stock.
Xenetic Biosciences Inc (NASDAQ: XBIO) is a clinical-stage biopharmaceutical leader advancing novel immuno-oncology therapies through its DNase platform and polyxen™ technology. This page provides investors and researchers with centralized access to the company’s latest developments in cancer treatment innovation.
Find timely updates on XBIO’s clinical trial progress, strategic collaborations, and regulatory milestones. Our curated collection includes press releases about orphan-designated therapies, CAR T platform advancements, and preclinical research insights – all essential for tracking the company’s contributions to targeted cancer treatments.
Key updates cover three focus areas: clinical developments in hard-to-treat cancers, technology partnerships enhancing therapeutic efficacy, and scientific publications validating novel approaches to tumor microenvironment modulation. Bookmark this page to stay informed about Xenetic’s progress in developing next-generation biologics and combination therapies.
Xenetic Biosciences (NASDAQ:XBIO) presented positive preclinical data showing the potential of co-administering DNase I with CAR T cells in treating melanoma lung metastasis. The study demonstrated that a single injection of DNase I (10 mg/kg) with EGFR-CAR T cells significantly suppressed metastatic tumor burden and extended survival compared to CAR T cell therapy alone. Key findings showed that DNase I increases tumor-infiltrating T and CAR T cells while reducing immunosuppressive effects. The research supports DNase I's potential as an adjunctive treatment to improve CAR T cell therapy responses, particularly in solid tumors where traditional CAR T cell therapy has shown efficacy.
Xenetic Biosciences (NASDAQ:XBIO) reported Q3 2024 financial results, showing a net loss of $0.4 million. R&D expenses decreased by 63.9% to $0.4 million compared to $1.0 million in Q3 2023, primarily due to reduced spending on DNase platform development. The company continues advancing its DNase-based oncology program towards Phase 1 clinical trials for pancreatic carcinoma and other solid tumors. Preliminary preclinical studies combining DNase I with chemotherapy, immuno-therapies, and CAR-T therapy in colorectal cancer models have been completed. The company ended Q3 with $6.8 million in cash.
Xenetic Biosciences (NASDAQ:XBIO) presented positive preclinical data demonstrating that DNase I significantly enhances the effectiveness of anti-CTLA-4 immune checkpoint blockade in colorectal carcinoma models. The study showed that systemic DNase I combined with α-CTLA-4 antibody successfully promoted antitumor immunity and generated immunological memory against microsatellite stable, mismatch repair proficient colorectal carcinoma tumors. Key findings include tumor growth inhibition, complete responses in mice, and enhanced survival rates. The data suggests DNase I impedes neutrophil tumor infiltration while promoting T cell infiltration and activation, potentially addressing unmet needs in cancer treatments where immune checkpoint inhibitors have shown efficacy.
Xenetic Biosciences (NASDAQ:XBIO) announced that its abstract has been accepted for poster presentation at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting. The event will take place from November 6-10, 2024, in Houston, Texas and virtually.
The presentation details are as follows:
- Title: DNase I Targeting of Neutrophil Extracellular Traps Improves CTLA-4 Immune Checkpoint blockade in Models of MSS/MMRp CRC
- Abstract Number: 765
- Presenter: Reid Bissonnette, Ph.D., Executive Consultant for Translational Research and Development at Xenetic
- Date and Time: Friday, November 8, 2024, 9:00 a.m.-7:00 p.m. CST
- Location: George R. Brown Convention Center -Level 1 -Exhibit Halls AB
Xenetic Biosciences (NASDAQ:XBIO) has entered into a Materials Transfer Agreement with Tokyo Medical University to advance its systemic DNase program. The agreement involves evaluating the effects of human recombinant DNase I (rhDNase I) in combination with chemotherapy for Ewing sarcoma, an aggressive pediatric cancer.
Professor Takuro Nakamura will lead the research using a proprietary immunocompetent preclinical mouse model. This model reflects the characteristics of human Ewing sarcoma and has shown translational relevance. The study aims to assess DNase's ability to reduce neutrophil extracellular traps (NETs) in the tumor microenvironment and enhance chemotherapy efficacy.
Previous clinical studies at Tel Aviv Medical Center demonstrated that NETs formation in Ewing sarcoma tumors is an independent prognostic factor, with higher NETs levels associated with poor prognosis and treatment response.
Xenetic Biosciences (NASDAQ:XBIO), a biopharmaceutical company focusing on innovative immune-oncology technologies for hard-to-treat cancers, announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference. Jim Parslow, the company's Interim CEO and CFO, delivered a presentation at the event. The video webcast of this presentation is now available on the Events page in the Investors section of Xenetic's website (www.XeneticBio.com) and will remain accessible for 90 days.
Xenetic Biosciences (NASDAQ:XBIO) reported its Q2 2024 financial results and provided a business update. Key highlights include:
1. Ongoing preclinical studies with data expected before year-end
2. Focus on demonstrating DNase-based oncology program in clinical proof-of-concept studies
3. Q2 2024 net loss of $1.3 million
4. R&D expenses remained flat at $0.9 million
5. G&A expenses increased by 19.5% to $1.1 million
6. Royalty payments of $0.7 million, an 11.6% increase year-over-year
7. Cash position of $7.3 million at quarter-end
The company remains confident in its DNase-based oncology platform and is advancing towards Phase 1 clinical development for pancreatic carcinoma and other solid tumors.
Xenetic Biosciences has announced the appointment of James F. Parslow as the interim Chief Executive Officer, effective May 16, 2024. Parslow, currently the Chief Financial Officer, will lead the company as it focuses on advancing its immune-oncology technologies. The company aims to drive its pipeline toward a first human clinical study and extend its cash runway. Xenetic is moving forward with its DNase-based oncology program, targeting pancreatic carcinoma and other advanced solid tumors, with preclinical data expected by year-end.
Xenetic Biosciences, Inc. reported its financial results for the first quarter of 2024, highlighting ongoing preclinical studies, advancement of DNase-based oncology program, and ending the quarter with $7.8 million in cash. The net loss for the quarter was approximately $1.2 million, with research & development expenses increasing by 58.6% and general and administrative expenses decreasing by 9.8% compared to the same quarter in 2023.
